ライフサイエンスコーパス: hand-foot syndrome

1 7-3.68, p=0.013, respectively), but not with hand-foot syndrome.

2 osal inflammation, fatigue, neutropenia, and hand-foot syndrome.

3 sity and included fatigue, hypertension, and hand-foot syndrome.

4 s included diarrhea, skin rash, fatigue, and hand-foot syndrome.

5 ocytopenia, asthenia, fatigue, diarrhea, and hand-foot syndrome.

6 ausea and vomiting, fatigue, stomatitis, and hand-foot syndrome.

7 d one had a skin reaction resembling grade 3 hand-foot syndrome.

8 ted with more central line complications and hand-foot syndrome.

9 DLTs were stomatitis and hand-foot syndrome.

10 y, were neutropenia (57.4%, 55.7% and 5.5%), hand/foot syndrome (0%, 0% and 23.5%), and diarrhoea (1.

11 Diarrhea (14%) and hand-foot syndrome (10%) were the only treatment-related

12 Neutropenia (15%), alopecia (13%), and hand-foot syndrome (11%) were the only grade 3 or 4 trea

13 to 4 adverse effects were neutropenia (44%), hand-foot syndrome (11%), diarrhea (8%), lymphopenia (8%

14 [11%]) in the patients treated with CMF, and hand-foot syndrome (129 [12%]) and diarrhoea (67 [6%]) i

15 nsient transaminitis (50%), mucositis (24%), hand-foot syndrome (13%), transient hypoxia (13%), nause

16 usality grade 3 to 4 adverse events included hand-foot syndrome (16.1%), fatigue (16.1%), hypertensio

17 Treatment-related grade 3 hand-foot syndrome (17% v < 1%) and grade 3/4 diarrhea (

18 s; fatigue (13% v 11%); diarrhea (3% v 11%); hand-foot syndrome (2% v 20%); mucositis (6% v 5%); vomi

19 he most common grade 3-4 adverse events were hand-foot syndrome (201 [21%] of 963 in the capecitabine

20 nterest for bevacizumab or chemotherapy were hand-foot syndrome (21 [16%] vs nine [7%]), diarrhoea (n

21 pheral neuropathy (126 [27%] vs 25 [5%]) and hand-foot syndrome (21 [4%] vs 15 [3%]) were more freque

22 (78% v 72%), although a higher incidence of hand-foot syndrome (24% v 0%) and mucositis/stomatitis (

23 tigue (25% v 12%), diarrhea (23% v 13%), and hand-foot syndrome (26% v 3%).

24 neuropathy (27.1% v 11.2%) and more grade 2 hand/foot syndrome (28.5% v 3.3%) and diarrhea (13.7% v

25 atment-related grade 2/3 adverse events were hand-foot syndrome (29%), leukopenia/neutropenia (24%),

26 adverse reactions were hypertension (39.6%), hand-foot syndrome (32.1%), fatigue (32.1%), oral ulcers

27 ilone arm and mucositis/stomatitis (43%) and hand-foot syndrome (41.8%) in the PLD arm.

28 gher incidence of fatigue (63% vs. 55%), the hand-foot syndrome (50% vs. 29%), and thrombocytopenia (

29 hematologic grade 2 to 3 adverse events were hand-foot syndrome (57%) and fatigue (48%).

30 6 patients [7.0%] vs 2 patients [4.3%]), and hand-foot syndrome (6 patients [7.0%] vs 2 patients [4.3

31 [10%]) in 359 axitinib-treated patients and hand-foot syndrome (61 [17%]), hypertension (43 [12%]),

32 were fatigue (14 [60%]), anorexia (9 [39%]), hand-foot syndrome (7 [30%]), hypothyroidism (7 [30%]),

33 e fatigue (9% v 1%), asthenia (8% v 2%), and hand-foot syndrome (7% v 0%).

34 were fatigue (16%), hypertension (12%), and hand-foot syndrome (8%).

35 ion (12%), fatigue (11%), diarrhea (9%), and hand-foot syndrome (9%).

36 itinib and 102 [16%] patients on sorafenib), hand-foot syndrome (94 [15%] patients on sunitinib and 2

37 n standard treatment (P </= .004), but worse hand-foot syndrome and diarrhea (P < .005).

38 milar in both arms, although higher rates of hand-foot syndrome and diarrhea occurred in patients ran

39 e I study, the dose-limiting toxicities were hand-foot syndrome and diarrhea.

40 Hand-foot syndrome and mucositis were less frequent with

41 The PLD group experienced significantly more hand-foot syndrome and mucositis; the gemcitabine group

42 Typically, hand-foot syndrome and neurologic toxicity are lacking.

43 Dose-limiting toxicities were mucositis and hand-foot syndrome, and 12.0 mg/m2/d for 5 days was esta

44 sh (n = 2; 1 grade 3 and 1 grade 2), grade 2 hand-foot syndrome, and grade 3 fever.

45 , left ventricular systolic dysfunction, the hand-foot syndrome, and mucositis.

46 (84% v 78%; P = .027), with increased rash, hand-foot syndrome, and thrombocytopenia accounting for

47 Ten patients (24%) had grade 3 hand-foot syndrome, and two patients (5%) had grade 3 sk

48 equent treatment-related adverse events were hand-foot syndrome, diarrhea, and nausea or vomiting.

49 Other toxicities included hand-foot syndrome, diarrhea, hyperbilirubinemia, skin r

50 common treatment-related adverse events were hand-foot syndrome, diarrhea, nausea, vomiting, and fati

51 The most common toxicities were hand-foot syndrome, diarrhea, nausea/vomiting, and asthe

52 Adverse events included hypertension, hand-foot syndrome, diarrhea, transaminitis, and fatigue

53 e [9%]), stomatitis (none vs five [9%]), and hand-foot syndrome (four [8%] vs none).

54 4, 36 [6%]), fatigue (grade 3, 53 [9%]), and hand-foot syndrome (grade 3, 43 [7%]).

55 penia (grade 3, 99 [17%]; grade 4, 37 [6%]), hand-foot syndrome (grade 3, 63 [11%]), and hypertension

56 patic transaminitis, hyperbilirubinemia, and hand foot syndrome (HFS) on the troxacitabine plus ara-C

57 Hand-foot syndrome (HFS) is a common adverse effect of c

58 Hand-foot syndrome (HFS) is a dose-limiting side effect

59 Hand-foot syndrome (HFS) is a dose-limiting toxicity of

60 Hand-foot syndrome (HFS) is a frequently occurring adver

61 ion (18% v 12%), and hand-foot skin reaction/hand- foot syndrome (HFSR/HFS; 90% v 66%); grade 3 to 4

62 e 1/2) diarrhea occurred in 39% of patients, hand-foot syndrome in 15%, nausea in 27%, and mucositis

63 3 toxicity, the most frequent of which were hand-foot syndrome in 43 (20%) patients, diarrhoea in 16

64 effects (febrile neutropenia, mucositis, the hand-foot syndrome, infection, and hypertension) but wit

65 h increased toxic effects--specifically, the hand-foot syndrome, mucositis, and neutropenia.

66 europathy (n = 2), constipation (n = 1), and hand-foot syndrome (n = 1).

67 cities included the following: rash (n = 7), hand-foot syndrome (n = 9), metabolic (n = 10), GI (n =

68 sion (n=62 [14%]), asthenia (n=35 [8%]), and hand-foot syndrome (n=29 [6%]).

69 ents, regardless of severity, were alopecia, hand-foot syndrome, nausea, and fatigue.

70 iarrhea, stomatitis/oral syndromes, fatigue, hand-foot syndrome, neutropenia, thrombocytopenia, anemi

71 Three patients experienced grade 3 hand-foot syndrome; one of these patients had grade 3 di

72 (2) capecitabine/docetaxel developed grade 3 hand-foot syndrome or diarrhea during either their first

73 atologic skin and mucosal toxicities (either hand-foot syndrome or stomatitis), with dose modificatio

74 ated grade 2 or higher mucositis, diarrhoea, hand-foot syndrome, or fatigue.

75 y higher incidence of stomatitis (P < .001), hand-foot syndrome (P < .001), and neutropenic infection

76 Grade 3 hand-foot syndrome (P <.00001) and grade 3/4 hyperbiliru

77 s reactions are alopecia, hyperpigmentation, hand--foot syndrome, radiation recall, hypersensitivity,

78 rienced with sorafenib include hypertension, hand-foot syndrome, rash, diarrhea and fatigue.

79 XELOX with more grade 3 diarrhea and grade 3 hand-foot syndrome than FOLFOX-4.

80 ces were found in the incidence of diarrhea, hand-foot syndrome, thromboembolic events, or serious bl

81 Hand-foot syndrome was more common after sequential ther

82 Toxicity, except for hand-foot syndrome, was more severe in the combination a

83 rexia, stomatitis/oral pain, abdominal pain, hand-foot syndrome, weight loss, and hypertension.

84 Gastrointestinal side effects and hand-foot syndrome were more common with combination the

85 Stomatitis and hand-foot syndrome were the DLTs.

86 es, including diarrhea, nausea, fatigue, and hand-foot syndrome, were manageable.